Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics
European Archives of Oto-Rhino-Laryngology · 2024
DOI: 10.1007/s00405-024-08548-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Archives of Oto-Rhino-Laryngology, 2024. Verfasst von Elena Cantone und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology, Federico II University of Naples, Naples, Italy. Hauptthemen laut MEDLINE: COVID-19, Olfaction Disorders, Thioctic Acid. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Catania.
Abstract (Originalsprache)
Purpose
Although COVID-19 anosmia is often transient, patients with persistent olfactory dysfunction (pOD) can experience refractory parosmia and diminished smell. This study evaluated four putative therapies for parosmia in patients with chronic COVID-19 olfactory impairment.
Methods
After screening nasal endoscopy, 85 patients (49 female, 58%) with pOD and treatment-refractory parosmia were randomized to: (1) ultramicronized palmitoylethanolamide and luteolin + olfactory training (OT) ( umPEALUT group , n = 17), (2) alpha-lipoic acid + OT ( ALA group , n = 21), (3) umPEALUT + ALA + OT ( combination group , n = 28), or 4) olfactory training (OT) alone ( control group , n = 23). Olfactory function was assessed at baseline (T 0 ) and 6 months (T 1 ) using a parosmia questionnaire and Sniffin’ Sticks test of odor threshold, detection, and identification (TDI). Analyses included one-way ANOVA for numeric data and Chi-Square analyses for nominal data on parosmia.
Results
The umPEALUT group had the largest improvement in TDI scores (21.8 ± 9.4 to 29.7 ± 7.5) followed by the combination group (19.6 ± 6.29 to 27.5 ± 2.7), both p < 0.01. The control and ALA groups had no significant change. Patients in the combination and umPEALUT groups had significantly improved TDI scores compared to ALA and control groups (p < 0.001). Rates of parosmia resolution after 6 months were reported at 96% for combination, 65% for control, 53% for umPEALUT and 29% for ALA (p < 0.001). All treatment regimens were well-tolerated. Conclusions umPEALUT and OT, with or without ALA, was associated with improvement in TDI scores and parosmia, whereas OT alone or OT with ALA were associated with little benefit.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Otolaryngology, Federico II University of Naples, Naples, Italy.
- Department of Otolaryngology, Ospedali Riuniti Marche Nord, Fano, Italy.
- Department of Otolaryngology, Fatebenefratelli Isola Tiberina-Gemelli Isola, Rome, Italy.
- Psychology Department, UTIU, Rome, Italy.
- GF Ingrassia Department, University of Catania, Catania, Italy.
- Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI, USA.
Förderung
- Università degli Studi di Catania
Zitieren
APA
Cantone, E., D'Ascanio, L., De Luca, P., Roccamatisi, D., La La Mantia, I., Brenner, M. J., & Di Stadio, A. (2024). Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics. European Archives of Oto-Rhino-Laryngology. https://doi.org/10.1007/s00405-024-08548-6
Vancouver
Cantone E, D'Ascanio L, De Luca P, Roccamatisi D, La La Mantia I, Brenner MJ, et al. Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics. European Archives of Oto-Rhino-Laryngology. 2024. doi:10.1007/s00405-024-08548-6
BibTeX
@article{Cantone2024,
author = {Cantone, Elena and D'Ascanio, Luca and De Luca, Pietro and Roccamatisi, Dalila and La La Mantia, Ignazio and Brenner, Michael J and Di Stadio, Arianna},
title = {Persistent COVID-19 parosmia and olfactory loss post olfactory training: randomized clinical trial comparing central and peripheral-acting therapeutics},
journal = {European Archives of Oto-Rhino-Laryngology},
year = {2024},
doi = {10.1007/s00405-024-08548-6}
}
EUVIMED